Nothing Special   »   [go: up one dir, main page]

SG11201906464UA - Csf1r-based chimeric proteins - Google Patents

Csf1r-based chimeric proteins

Info

Publication number
SG11201906464UA
SG11201906464UA SG11201906464UA SG11201906464UA SG11201906464UA SG 11201906464U A SG11201906464U A SG 11201906464UA SG 11201906464U A SG11201906464U A SG 11201906464UA SG 11201906464U A SG11201906464U A SG 11201906464UA SG 11201906464U A SG11201906464U A SG 11201906464UA
Authority
SG
Singapore
Prior art keywords
international
csf1r
bowman
austin
ave
Prior art date
Application number
SG11201906464UA
Inventor
Taylor Schreiber
George Fromm
Silva Suresh De
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of SG11201906464UA publication Critical patent/SG11201906464UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epidemiology (AREA)

Abstract

CCSF1R . 0 Li? ANTIGEN PRESENTING CELL NO ARC PRESENT CSF1 IL-34 CSFia_e IL-34 4 SUPPRESSION ACTIVATION CSF1R-Fc-CD4OL 7k. \":\" 4ACTIVATION VIA CD40 COMPETITIVE INHIBITION OF CSF1R (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIP0 I PCT IiiimmomiolollmonolomolloomomioommovoimIE (10) International Publication Number WO 2018/157164 Al 1-1 71- 1-1 N 1-1 00 (51) International Patent Classification: A61K 38/00 (2006.01) C07K 19/00 (2006.01) C07K 14/705 (2006.01) C12N 15/11 (2006.01) (21) International Application Number: PCT/US2018/020039 (22) International Filing Date: 27 February 2018 (27.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/463,997 27 February 2017 (27.02.2017) US (71) Applicant: SHATTUCK LABS, INC. [US/US]; 3317 Bowman Ave., Austin, TX 78703 (US). (72) Inventors: SCHREIBER, Taylor; 3317 Bowman Ave., Austin, TX 78703 (US). FROMM, George; 3317 Bowman Ave., Austin, TX 78703 (US). DE SILVA, Suresh; 3317 Bowman Ave., Austin, TX 78703 (US). (74) Agent: ALTIERI, Stephen, L. et al.; Morgan, Lewis & Bockius LLP, 1111 Pennsylvania Avenue, NW, Washing- ton, DC 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: CSF1R-BASED CHIMERIC PROTEINS FIG. - IA el (57) : The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating 0 factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
SG11201906464UA 2017-02-27 2018-02-27 Csf1r-based chimeric proteins SG11201906464UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762463997P 2017-02-27 2017-02-27
PCT/US2018/020039 WO2018157164A1 (en) 2017-02-27 2018-02-27 Csf1r-based chimeric proteins

Publications (1)

Publication Number Publication Date
SG11201906464UA true SG11201906464UA (en) 2019-08-27

Family

ID=63253352

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906464UA SG11201906464UA (en) 2017-02-27 2018-02-27 Csf1r-based chimeric proteins

Country Status (15)

Country Link
US (4) US11267856B2 (en)
EP (1) EP3585409A4 (en)
JP (2) JP7121029B2 (en)
KR (1) KR20190124247A (en)
CN (1) CN110381974A (en)
AU (1) AU2018223822A1 (en)
BR (1) BR112019017713A2 (en)
CA (1) CA3054132A1 (en)
IL (1) IL268197A (en)
MX (1) MX2019010173A (en)
PH (1) PH12019501534A1 (en)
SA (1) SA519402522B1 (en)
SG (1) SG11201906464UA (en)
WO (1) WO2018157164A1 (en)
ZA (1) ZA201906235B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201906464UA (en) 2017-02-27 2019-08-27 Shattuck Labs Inc Csf1r-based chimeric proteins
AU2020228053A1 (en) * 2019-02-28 2021-09-23 Shattuck Labs, Inc. Combination therapies
WO2020257762A1 (en) * 2019-06-21 2020-12-24 Shattuck Labs, Inc. Chimeric protein expressing t-cells
CN111068054B (en) * 2019-11-06 2022-02-11 浙江大学医学院附属第一医院 Medicament for treating tumor by using CSF1R as drug target and preparation method thereof
WO2021129673A1 (en) * 2019-12-24 2021-07-01 Adagene (Suzhou) Limited Anti-csf1r molecules and use thereof
KR102671409B1 (en) * 2021-03-02 2024-05-31 진화섭 Recombinant protein which induces cytotoxicity in CD30 expressing cell and the composition comprising the same for treating cancer
KR20230012129A (en) * 2021-07-14 2023-01-26 주식회사 이뮤노로지컬디자이닝랩 Chimeric antigen receptor specifically binding to CD30 and use thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
DE69233402T3 (en) * 1991-10-25 2009-06-25 Immunex Corp., Seattle NEW CYTOKINE
CA2395945C (en) 2000-01-03 2013-12-24 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
US20110041190A1 (en) 2002-10-31 2011-02-17 Tykocinski Mark L Novel chimeric proteins
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
WO2005047335A1 (en) 2003-11-13 2005-05-26 Hanmi Pharmaceutical. Co., Ltd. Method for themass production of immunoglobulin constant region
JP2006345852A (en) 2005-06-16 2006-12-28 Virxsys Corp Antibody conjugate
JP2009537145A (en) 2006-05-15 2009-10-29 バイラル ロジック システムズ テクノロジー コーポレーション Compositions and methods associated with CD47 for treating immunological diseases and disorders
KR101571027B1 (en) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Single-chain multivalent binding proteins with effector function
US20100150931A1 (en) 2006-11-22 2010-06-17 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
JP5547656B2 (en) 2008-01-15 2014-07-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Methods for manipulating phagocytosis mediated by CD47
EP2262531A1 (en) 2008-03-08 2010-12-22 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
CA2729351C (en) 2008-06-30 2017-01-24 University Of Pennsylvania Fn14/trail fusion proteins
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
MX2011006621A (en) 2008-12-19 2011-07-12 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders.
CA2755198A1 (en) 2009-03-13 2010-09-16 Mark L. Tykocinski Ox40/trail fusion proteins
CA2791383C (en) 2010-03-05 2022-09-20 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CN103153332A (en) 2010-09-28 2013-06-12 卡尔医疗有限公司 Compositions and methods for treatment of hematological malignancies
CN107090029B (en) 2010-11-11 2021-07-13 港大科桥有限公司 Soluble PD-1 variants, fusion constructs, and uses thereof
LT2697257T (en) 2011-04-13 2016-12-27 Bristol-Myers Squibb Company Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS
WO2012162565A2 (en) 2011-05-25 2012-11-29 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
CN102850458B (en) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 Novel recombined dual-function fusion protein and its preparation method and application
JP6334398B2 (en) 2011-07-29 2018-05-30 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Switch costimulatory receptors
US9828432B2 (en) 2012-02-06 2017-11-28 Providence Health & Services—Oregon Cancer treatment and monitoring methods using OX40 agonists
AU2013255542C1 (en) 2012-04-30 2017-06-22 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
ES2924722T3 (en) 2012-05-18 2022-10-10 Aptevo Res & Development Llc Immunofusion binding of bispecific scFv (BIf) to CD123 and CD3
CN112587671A (en) 2012-07-18 2021-04-02 博笛生物科技有限公司 Targeted immunotherapy for cancer
KR20200140400A (en) * 2012-08-31 2020-12-15 파이브 프라임 테라퓨틱스, 인크. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
ES2914814T3 (en) 2012-12-17 2022-06-16 Pf Argentum Ip Holdings Llc Treatment of diseased CD47+ cells with SIRP Alpha-Fc fusions
CN105026424A (en) 2013-01-01 2015-11-04 卡尔医疗有限公司 Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for modulating regulatory and effector t cells
WO2014121093A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
WO2014121085A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
DK2961831T3 (en) 2013-02-26 2020-09-07 Memorial Sloan Kettering Cancer Center Compositions and methods of immunotherapy
CN105121474B9 (en) 2013-03-12 2020-06-19 比奥孔有限公司 Fusion immunomodulatory protein and preparation method thereof
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US10927154B2 (en) 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
US20170015758A1 (en) 2014-01-21 2017-01-19 Medimmune, Llc Compositions And Methods For Modulating And Redirecting Immune Responses
WO2015148416A1 (en) 2014-03-24 2015-10-01 Deqiang Jing Novel recombinant bi-functional fusion proteins, preparation and use thereof
CN106456734A (en) 2014-05-29 2017-02-22 免疫医疗有限责任公司 OX40L fusion proteins and uses thereof
EP3160497A4 (en) 2014-06-27 2018-01-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
TWI702228B (en) 2014-08-08 2020-08-21 美商Ａｌｘ腫瘤技術股份有限公司 Sirp-alpha variant constructs and uses thereof
NZ728175A (en) 2014-08-11 2023-03-31 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
HUE046661T2 (en) 2014-08-15 2020-03-30 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins
MX2017006320A (en) 2014-11-17 2017-08-10 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists.
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (en) 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES
AU2016215175B2 (en) 2015-02-06 2021-09-16 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
WO2016168149A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
JP7064234B2 (en) 2015-05-18 2022-05-10 エービー イニチオ バイオセラピューティクス，インク． SIRP polypeptide composition and method of use
US10259859B2 (en) 2015-08-07 2019-04-16 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
CN116063566A (en) * 2015-10-01 2023-05-05 热生物制品有限公司 Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. Therapeutic cd47 antibodies
SG11201906464UA (en) 2017-02-27 2019-08-27 Shattuck Labs Inc Csf1r-based chimeric proteins

Also Published As

Publication number Publication date
EP3585409A4 (en) 2020-12-02
RU2019129835A (en) 2021-03-29
PH12019501534A1 (en) 2019-09-09
CN110381974A (en) 2019-10-25
US20220144909A1 (en) 2022-05-12
AU2018223822A1 (en) 2019-07-11
SA519402522B1 (en) 2023-03-12
BR112019017713A2 (en) 2020-04-07
JP2022159393A (en) 2022-10-17
EP3585409A1 (en) 2020-01-01
US20190169249A1 (en) 2019-06-06
US20190382466A1 (en) 2019-12-19
US11267856B2 (en) 2022-03-08
RU2019129835A3 (en) 2021-07-16
KR20190124247A (en) 2019-11-04
MX2019010173A (en) 2019-11-21
US20200123214A1 (en) 2020-04-23
US10513548B2 (en) 2019-12-24
IL268197A (en) 2019-09-26
JP2020508063A (en) 2020-03-19
ZA201906235B (en) 2021-04-28
JP7121029B2 (en) 2022-08-17
CA3054132A1 (en) 2018-08-30
US11267857B2 (en) 2022-03-08
WO2018157164A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
SG11201906464UA (en) Csf1r-based chimeric proteins
SG11201906465YA (en) Tigit- and light-based chimeric proteins
SG11201909949XA (en) Targeted immunotolerance
SG11201804118VA (en) Compositions comprising bacterial strains
SG11201809064QA (en) Chimeric neurotoxins
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201806302RA (en) Inhibitors of receptor-interacting protein kinase 1
SG11201804162WA (en) Compositions comprising bacterial strains
SG11201804211YA (en) Compositions comprising bacterial strains
SG11201900596XA (en) Cannabis composition
SG11201811432WA (en) Rna for cancer therapy
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201809764XA (en) Humanized anti-il-1r3 antibodies
SG11201808108XA (en) Synthesis of indazoles
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201908275XA (en) Peptides and methods for the treatment of diabetes